Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects

Bone Marrow Transplantation

Volumn 33, Issue 12, 2004, Pages 1191-1199

  Thall, P F ^a   Champlin, R E ^a   Andersson, B S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bayesian statistics; Busulfan; Cyclophosphamide; Stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; METHOTREXATE; MYELOABLATIVE AGENT; TACROLIMUS;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BAYES THEOREM; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; BAYES THEOREM; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 3242709629     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704461     Document Type: Article

References (44)

1. Horowitz MM. Results of allogeneic stem cell transplantation for malignant disorders. In: Hoffman R, Benz Jr EJ, Shattil SJ, Fine B, Cohen H, Silberstein LE, McGlave P (eds). Hematology, Basic Principles and Practice, 3rd edn. Churchill Livingston, New York, NY, 2000; pp 1573-1587.
2. International Bone Marrow Transplant Registry. September 2000.
3. Bushhouse S, Ramsay NK, Pescovitz OH et al. Growth in children following irradiation for bone marrow transplantation. Am J Ped Hematol/Oncol 1989; 11: 134-140.
4. Sanders JE. Bone marrow transplantation for pediatric leukemia. Pediat Ann 1991; 20: 671-676.
5. Liesner RJ, Leiper AD, Hann IM et al. Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood. J Clin Oncol 1994; 12: 916-924.
6. Cohen A, van-Lint MT, Uderzo C et al. Growth in patients after allogeneic bone marrow transplant for hematological diseases in childhood. Bone Marrow Transplant 1995; 15: 343-348.
7. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
8. Chou RH, Wong GB, Kramer JH et al. Toxicities of total-body irradiation for pediatric bone marrow transplantation. Int J Radiat Oncol Biol Phys 1996; 34: 843-851.
9. Deeg HJ, Socié G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386-392.
10. Kony SJ, de Vathaire F, Chompret A et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet 1997; 350: 91-95.
11. Deeg HJ, Socié G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
12. Socié G, Curtis RE, Deeg HJ et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348-357.
13. Santos GW, Tutschka PJ, Brookmeyer R et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
14. Lu C, Braine HG, Kaizer H et al. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat Rep 1984; 68: 711-717.
15. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382-1388.
16. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036-2043.
17. Clift RA, Radich J, Appelbaum FR et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 1999; 94: 3960-3962.
18. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
19. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncology 1993; 20 (Suppl. 4): 18-25.
20. Hassan M, Öberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525-530.
21. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
22. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
23. Styler MJ, Crilley P, Biggs J et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant 1996; 18: 171-176.
24. Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203-6207.
25. Peters WP, Henner WD, Grochow LB et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987; 47: 6402-6406.
26. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review). Anticancer Res 1994; 14: 2363-2370.
27. Andersson BS, Madden T, Tran H et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: A phase I Study. Biol Blood and Marrow Transplant 2000; 6: 548-554.
28. Hassan M. Busulphan. In: Grochow LB, Ames MM (eds). A Clinical Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Williams and Wilkins: New York, NY, 1997; pp 189-210.
29. Benet LZ, Sheiner LB. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Goodman Gilman A, Goodman LS, Rall TW, Murad F (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th edn. MacMillan Publishing Co.: New York, NY, 1985; p 8.
30. Bhagwatwar HP, Phadungpojna S, Chow DS et al. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996; 37: 401-408.
31. Andersson BS, Kashyap A, Gian V et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002; 8: 145-154.
32. Andersson BS, Thall PF, Madden T et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft vs. host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485.
33. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. Chapman & Hall: New York, NY, 1995.
34. Robert CP. The Bayesian Choice, 2nd edn. Springer Verlag: New York, NY, 2001.
35. Estey E, Thall P, Giles F et al. Gemtuzumab ozogamycin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin + continuous-infusion high-dose cytosine arabinoside. Blood 2002; 99: 4343-4349.
36. Van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Medicine 1996; 100: 299-307.
37. Van Besien K, Thall P, Korbling M et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997; 3: 150-156.
38. Przepiorka D, Anderlini P, Ippoliti C et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997; 19: 455-460.
39. Przepiorka D, Khouri I, Thall PF et al. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant 1999; 23: 977-981.
40. Przepiorka D, Smith TL, Folloder J et al. Risk factors for actue graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
41. Przepiorka D, van Besien K, Khouri I et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol 1999; 10: 527-532.
42. Bibawi S, Abi-Said D, Fayad L et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 2001; 67: 227-233.
43. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
44. Radich JP, Gooley T, Bensinger W et al. HLA-matched related hematopoetic cell transplantation for CML chronic phase using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31-35.